Markowski Investments’s Recursion Pharmaceuticals RXRX Stock Holding History

Markowski Investments’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.86K	Buy	+780	New	+$2.6K	﹤0.01%	527

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Markowski Investments's RXRX Position: Q2 2026 in Review

Markowski Investments opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 780 shares worth $2.86K. The stake represents ﹤0.01% of the portfolio and ranks #527 among its holdings.

250 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Markowski Investments held 780 shares of Recursion Pharmaceuticals worth $2.86K as of Q2 2026.
Recursion Pharmaceuticals was a new Markowski Investments position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Markowski Investments's portfolio in Q2 2026, its #527 holding.
250 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Markowski Investments's 13F filing for Q2 2026, filed 13 Aug 2026.